Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia
1Department of Internal Medicine, Northeastern Ohio Universities, College of Medicine, Rootstown, Ohio, USA. filet@summa-health.org
Abstract:
Streptococcus pneumoniae, the most important respiratory tract pathogen implicated in community-acquired pneumonia (CAP), is becoming increasingly resistant in vitro to the beta -lactams and macrolides, and fluoroquinolone resistance has been detected. A growing body of evidence suggests that prolonged antimicrobial use may contribute directly and indirectly to increased antimicrobial resistance among common respiratory pathogens. Long-term exposure to antimicrobial agents, especially less-potent agents, directly increases selection pressure for resistance. Indirectly, poor patient compliance, multiple daily dosing, and the increased risk of adverse events further complicate the resistance issue and diminish the efficacy of long-term antimicrobial use. Controlled clinical trials addressing the appropriate duration of therapy for CAP are lacking. However, available data suggest that with appropriate antibiotic selection, based on appropriate spectrum, potency, and pharmacokinetic/pharmacodynamic profile, lower respiratory tract infections in outpatients can be successfully treated in <7 days rather than the 7-14 days currently recommended.
Insights
Shorter antibiotic courses, less than 7 days, may effectively treat community-acquired pneumonia (CAP). Appropriate antibiotic selection is key to reducing antimicrobial resistance and improving treatment outcomes for respiratory infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Streptococcus pneumoniae is a primary cause of community-acquired pneumonia (CAP).
- Increasing antimicrobial resistance to beta-lactams, macrolides, and fluoroquinolones is a significant concern.
- Prolonged antimicrobial use is linked to increased resistance in respiratory pathogens through direct selection pressure and indirect factors like poor compliance.
Purpose of the Study:
- To evaluate the optimal duration of antibiotic therapy for community-acquired pneumonia (CAP).
- To investigate the impact of prolonged antimicrobial use on resistance patterns.
- To determine if shorter treatment durations (<7 days) are effective for CAP.
Main Methods:
- Review of available data and evidence regarding antimicrobial use and resistance.
- Analysis of factors contributing to antimicrobial resistance.
- Comparison of recommended treatment durations (7-14 days) with potential shorter durations (<7 days).
Main Results:
- Evidence suggests prolonged antimicrobial exposure increases resistance.
- Factors like poor compliance and adverse events complicate long-term therapy.
- Data indicate successful outpatient treatment of lower respiratory tract infections in <7 days is possible with appropriate antibiotic selection.
Conclusions:
- Controlled clinical trials on CAP therapy duration are needed.
- Appropriate antibiotic selection (spectrum, potency, PK/PD) is crucial.
- Shorter antibiotic courses (<7 days) may be effective for CAP, challenging the current 7-14 day recommendations.
More Related Videos
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Antimicrobial Effectiveness
01:14Atypical Pneumonia